Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.870
-0.020 (-1.06%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Company Description
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
| Phone | (908) 967-6677 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| Employer ID | 99-4362660 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chief Executive Officer, President and Executive Chairman |
| Myron Z. Holubiak | Secretary and Executive Vice Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 19, 2025 | 8-K | Current Report |
| Sep 12, 2025 | SCHEDULE 13D/A | Filing |
| Sep 10, 2025 | 424B3 | Prospectus |
| Sep 10, 2025 | 8-K | Current Report |
| Sep 10, 2025 | 424B5 | Filing |
| Sep 4, 2025 | EFFECT | Notice of Effectiveness |
| Sep 2, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 20, 2025 | DRS | [Cover] Draft Registration Statement |